Lymphoma, T-Cell, Peripheral
"Lymphoma, T-Cell, Peripheral" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.
MeSH Number(s)
C04.557.386.480.750.825
C15.604.515.569.480.750.825
C20.683.515.761.480.750.825
Concept/Terms
Lymphoma, T-Cell, Peripheral- Lymphoma, T-Cell, Peripheral
- T-Cell Lymphoma, Peripheral
- T Cell Lymphoma, Peripheral
- Lymphoma, T Cell, Peripheral
- Peripheral T-Cell Lymphoma
- Lymphoma, Peripheral T-Cell
- Lymphomas, Peripheral T-Cell
- Peripheral T Cell Lymphoma
- Peripheral T-Cell Lymphomas
- T-Cell Lymphomas, Peripheral
Below are MeSH descriptors whose meaning is more general than "Lymphoma, T-Cell, Peripheral".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Lymphoma [C04.557.386]
- Lymphoma, Non-Hodgkin [C04.557.386.480]
- Lymphoma, T-Cell [C04.557.386.480.750]
- Lymphoma, T-Cell, Peripheral [C04.557.386.480.750.825]
- Hemic and Lymphatic Diseases [C15]
- Lymphatic Diseases [C15.604]
- Lymphoproliferative Disorders [C15.604.515]
- Lymphoma [C15.604.515.569]
- Lymphoma, Non-Hodgkin [C15.604.515.569.480]
- Lymphoma, T-Cell [C15.604.515.569.480.750]
- Lymphoma, T-Cell, Peripheral [C15.604.515.569.480.750.825]
- Immune System Diseases [C20]
- Immunoproliferative Disorders [C20.683]
- Lymphoproliferative Disorders [C20.683.515]
- Lymphoma [C20.683.515.761]
- Lymphoma, Non-Hodgkin [C20.683.515.761.480]
- Lymphoma, T-Cell [C20.683.515.761.480.750]
- Lymphoma, T-Cell, Peripheral [C20.683.515.761.480.750.825]
Below are MeSH descriptors whose meaning is more specific than "Lymphoma, T-Cell, Peripheral".
This graph shows the total number of publications written about "Lymphoma, T-Cell, Peripheral" by people in Harvard Catalyst Profiles by year, and whether "Lymphoma, T-Cell, Peripheral" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 3 | 0 | 3 |
| 2003 | 1 | 1 | 2 |
| 2004 | 2 | 0 | 2 |
| 2005 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 2 | 0 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 6 | 0 | 6 |
| 2012 | 2 | 0 | 2 |
| 2013 | 3 | 0 | 3 |
| 2014 | 8 | 0 | 8 |
| 2015 | 4 | 0 | 4 |
| 2016 | 4 | 0 | 4 |
| 2017 | 2 | 1 | 3 |
| 2018 | 4 | 0 | 4 |
| 2019 | 8 | 0 | 8 |
| 2020 | 1 | 0 | 1 |
| 2021 | 4 | 0 | 4 |
| 2022 | 11 | 0 | 11 |
| 2023 | 3 | 0 | 3 |
Below are the most recent publications written about "Lymphoma, T-Cell, Peripheral" by people in Profiles.
-
A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma. Blood. 2023 08 17; 142(7):621-628.
-
Mogamulizumab-Associated Myositis With and Without Myasthenia Gravis and/or Myocarditis in Patients With T-Cell Lymphoma. Oncologist. 2023 08 03; 28(8):e694-e698.
-
The prognostic role of red cell distribution width on all-cause and cause-specific outcomes in peripheral T-cell lymphoma: a retrospective cohort study. Leuk Lymphoma. 2023 Jul-Aug; 64(7):1225-1233.
-
Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma. Oncologist. 2022 Oct 01; 27(10):864-873.
-
TCL-318 Evaluation of the Antitumor Activity of Amiloride in Peripheral T-Cell Lymphomas Using In-Vitro Models. Clin Lymphoma Myeloma Leuk. 2022 Oct; 22 Suppl 2:S399.
-
DNMT3A mutations define a unique biological and prognostic subgroup associated with cytotoxic T cells in PTCL-NOS. Blood. 2022 09 15; 140(11):1278-1290.
-
Comparative efficacy and tolerability of novel agents vs chemotherapy in relapsed and refractory T-cell lymphomas: a meta-analysis. Blood Adv. 2022 08 23; 6(16):4740-4762.
-
Poor outcome of CHOEP induction followed by gemcitabine/busulfan/melphalan high-dose therapy and stem cell rescue for patients with newly diagnosed peripheral T-cell lymphoma. Bone Marrow Transplant. 2022 11; 57(11):1719-1720.
-
Gene Expression Signatures for the Accurate Diagnosis of Peripheral T-Cell Lymphoma Entities in the Routine Clinical Practice. J Clin Oncol. 2022 12 20; 40(36):4261-4275.
-
Comparative outcomes for mature T-cell and NK/T-cell lymphomas in people with and without HIV and to AIDS-defining lymphomas. Blood Adv. 2022 03 08; 6(5):1420-1431.